Dianthus Therapeutics Relocates HQ to NYC, Updates Phone

TL;DR

**Dianthus Therapeutics moved its main office to New York City, signaling a potential strategic shift.**

AI Summary

Dianthus Therapeutics, Inc. filed an 8-K on January 8, 2024, to update its principal executive offices from Cambridge, MA to 7 Times Square, 43rd Floor, New York, NY 10036, and changed its business phone number to 929-999-4055. This administrative change signals a potential shift in operational focus or leadership location, which could impact investor perception of the company's strategic direction, though it doesn't directly affect its financial condition or results of operations.

Why It Matters

This filing indicates a significant administrative change for Dianthus Therapeutics, moving its headquarters to New York City. While not directly financial, such a move can signal strategic shifts, potential new leadership, or access to different talent pools, which could indirectly influence the company's future performance and investor sentiment.

Risk Assessment

Risk Level: low — This filing primarily reports an administrative change of address and phone number, which carries minimal direct financial or operational risk.

Analyst Insight

A smart investor would note this administrative change but understand it has no immediate financial impact. They might monitor future announcements for strategic shifts or new hires that could be associated with the move to New York City, as this could signal a change in corporate direction or access to different capital markets.

Key Players & Entities

• Dianthus Therapeutics, Inc. (company) — the registrant filing the 8-K
• 7 Times Square, 43rd Floor, New York, New York 10036 (location) — new principal executive offices
• 929-999-4055 (number) — new business telephone number
• 300 Technology Square, 8th Floor, Cambridge, MA 02139 (location) — former business address
• January 8, 2024 (date) — date of earliest event reported

Forward-Looking Statements

• Dianthus Therapeutics may announce new leadership or strategic initiatives in the coming months, potentially linked to its New York City relocation. (Dianthus Therapeutics, Inc.) — medium confidence, target: 2024-07-08

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 Par Value DNTH The Nasdaq Capital M
• $173 million — short-term investments of approximately $173 million as of December 31, 2023. A copy of the

Filing Documents

• dnth-20240108.htm (8-K) — 47KB
• dnth-ex99_1.htm (EX-99.1) — 26KB
• dnth-ex99_1s1.jpg (GRAPHIC) — 465KB
• dnth-ex99_1s2.jpg (GRAPHIC) — 592KB
• dnth-ex99_1s3.jpg (GRAPHIC) — 515KB
• dnth-ex99_1s4.jpg (GRAPHIC) — 562KB
• dnth-ex99_1s5.jpg (GRAPHIC) — 390KB
• dnth-ex99_1s6.jpg (GRAPHIC) — 144KB
• dnth-ex99_1s7.jpg (GRAPHIC) — 405KB
• dnth-ex99_1s8.jpg (GRAPHIC) — 492KB
• dnth-ex99_1s9.jpg (GRAPHIC) — 438KB
• dnth-ex99_1s10.jpg (GRAPHIC) — 471KB
• dnth-ex99_1s11.jpg (GRAPHIC) — 380KB
• dnth-ex99_1s12.jpg (GRAPHIC) — 131KB
• dnth-ex99_1s13.jpg (GRAPHIC) — 331KB
• dnth-ex99_1s14.jpg (GRAPHIC) — 375KB
• dnth-ex99_1s15.jpg (GRAPHIC) — 344KB
• dnth-ex99_1s16.jpg (GRAPHIC) — 525KB
• dnth-ex99_1s17.jpg (GRAPHIC) — 428KB
• dnth-ex99_1s18.jpg (GRAPHIC) — 469KB
• dnth-ex99_1s19.jpg (GRAPHIC) — 472KB
• dnth-ex99_1s20.jpg (GRAPHIC) — 111KB
• dnth-ex99_1s21.jpg (GRAPHIC) — 409KB
• dnth-ex99_1s22.jpg (GRAPHIC) — 550KB
• dnth-ex99_1s23.jpg (GRAPHIC) — 111KB
• dnth-ex99_1s24.jpg (GRAPHIC) — 366KB
• dnth-ex99_1s25.jpg (GRAPHIC) — 430KB
• 0000950170-24-002707.txt ( ) — 13876KB
• dnth-20240108.xsd (EX-101.SCH) — 54KB
• dnth-20240108_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. Dianthus Therapeutics, Inc.’s (the “Company”) audited financial statements for the fiscal year ended December 31, 2023 are not yet available. Beginning on January 8, 2024, the Company plans to disclose in a presentation to investors (the Presentation) that it expects to report cash, cash equivalents, and short-term investments of approximately $173 million as of December 31, 2023. A copy of the Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The estimated cash, cash equivalents and short-term investments amount is preliminary and unaudited, represents management’s estimate as of the date of this report, is subject to completion of the Company’s financial closing procedures for the fourth quarter and fiscal year ended December 31, 2023, and does not present all necessary information for a complete understanding of the Company’s financial condition as of December 31, 2023, or the Company’s results of operations for the year ended December 31, 2023. The actual financial results may differ materially from the preliminary estimated financial information. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Spokespersons of the Company plan to present the information in the Presentation at various meetings beginning on January 8, 2024, including investor and analyst meetings. Marino Garcia, the Company's President and Chief Executive Officer, will also present the information in the Presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward-Looking Statements. The Presentation contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes in the Presentation regarding these forward-looking statements.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation of Dianthus Therapeutics, Inc., dated January 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIANTHUS THERAPEUTICS, INC. Date: January 8, 2024 By: /s/ Adam M. Veness, Esq. Adam M. Veness, Esq. SVP, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR